Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Neoplasm Metastasis 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hodgkin Disease 3Endometrial Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Mantle-Cell 2Thyroid cancer, follicular 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Recurrence 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Cancer 1

Interventions

Gemcitabine 39Cisplatin 24Oxaliplatin 21Capecitabine 20Fluorouracil 11Leucovorin 9Irinotecan 9130-nm albumin-bound paclitaxel 8durvalumab 6Taxes 5Radiotherapy 5Platinum 4Immunohistochemistry 4Erlotinib Hydrochloride 4Docetaxel 4Carboplatin 4Bevacizumab 4Albumin-Bound Paclitaxel 41,2-diaminocyclohexaneplatinum II citrate 4trifluridine tipiracil drug combination 3Trastuzumab 3Sorafenib 3Observation 3Epirubicin 3Drug Therapy 3tremelimumab 2toripalimab 2regorafenib 2pembrolizumab 2anlotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gallbladder Neoplasms × copanlisib × Clear all
NCT02631590 2021-08-04

Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
24 enrolled 11 charts
Gastrointestinal

Digestive System Neoplasms, Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡